ClinicalTrials.Veeva

Menu

TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

T

Telik

Status and phase

Completed
Phase 2
Phase 1

Conditions

Non-small Cell Lung Cancer

Treatments

Drug: TLK286, cisplatin

Study type

Interventional

Funder types

Industry

Identifiers

NCT00077883
TLK286.2021

Details and patient eligibility

About

The purpose of this trial is to study the efficacy and safety of the combination of TLK286 with cisplatin as first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer.

Enrollment

50 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 18 years of age or older
  • Histologically confirmed non-small cell lung cancer
  • Stage IV or IIIB
  • Measurable disease by RECIST
  • ECOG performance status of 0-1
  • Adequate liver and renal function
  • Adequate bone marrow reserve

Exclusion criteria

  • History of bone marrow transplantation or stem cell support
  • Pregnant or lactating women

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

3

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems